Status:
NOT_YET_RECRUITING
Vitiligo Registry for Adults and Children in the UK
Lead Sponsor:
The Royal Wolverhampton Hospitals NHS Trust
Collaborating Sponsors:
Incyte Biosciences International Sàrl
Conditions:
Dermatologic Disease
Vitiligo
Eligibility:
All Genders
Brief Summary
Vitiligo is the most common depigmentation disorder affecting around 1% of the population worldwide. Fifty two percent of patients develop vitiligo before the age of 20 and around 80% develop vitiligo...
Detailed Description
Vitiligo is the most common depigmentation disorder affecting around 1% of the population worldwide. Fifty two percent of patients develop vitiligo before the age of 20 and around 80% develop vitiligo...
Eligibility Criteria
Inclusion
- Paediatric and adult patients with vitiligo under management in secondary care.
- Written informed consent for study participation obtained from the patient or parents / legal guardian, with assent as appropriate by the patient, depending on the level of understanding.
- Participants consent to participate in long-term follow up and access to all relevant medical records as needed by the study team
- Clinical diagnosis of vitiligo made by a dermatologist
- Willingness to comply with all study requirements.
- Competent use of English language, according to patient's age (capable of understanding patient questionnaires).
Exclusion
- Insufficient understanding of the study by the patient and/or parent/guardian.
- Patients with vitiligo/their parents or guardians, who do not provide consent for participation.
Key Trial Info
Start Date :
December 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 1 2029
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06218082
Start Date
December 15 2025
End Date
October 1 2029
Last Update
November 17 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Royal Wolverhampton NHS Trust
Wolverhampton, United Kingdom, WV10 0QP